Table 2 Association of FSCN1 expression with clinical pathological parameters in IDC patients.
From: EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Parameter | No. | FSCN1 Expression, n (%) | P-value |
|---|---|---|---|
Age (years) | |||
≤35 | 21 | 9 (42.9%) | 0.610 |
35–55 | 288 | 93 (32.3%) |  |
>55 | 158 | 52 (32.9) | Â |
Tumor size (cm) | |||
≤2 | 235 | 66 (28.1%) | 0.024 |
2–5 | 209 | 76 (36.4%) |  |
>5 | 23 | 12 (52.2%) | Â |
Lymphnode metastases | |||
− | 235 | 66 (28.1%) | 0.024 |
+ | 232 | 88 (37.9%) | Â |
Tumor grade | |||
I | 27 | 3 (11.1%) | 0.000 |
II | 329 | 82 (24.9%) | Â |
III | 111 | 69 (62.2%) | Â |
Tumor stage | |||
I | 140 | 35 (25.0%) | 0.045 |
II | 208 | 73 (35.1%) | Â |
III | 119 | 46 (38.7%) | Â |
IV | 0 | 0 (0.00) | Â |
Estrogen receptor | |||
− | 177 | 113 (63.8%) | 0.000 |
+ | 290 | 41 (14.1%) | Â |
Progesterone receptor | |||
− | 223 | 121 (54.3%) | 0.000 |
+ | 244 | 33 (13.5%) | Â |
c-erbB-2 expression | |||
0–1+ | 203 | 76 (37.4%) | 0.045 |
2+ | 154 | 39 (25.3%) | Â |
3+ | 110 | 39 (35.5%) | Â |
Molecular classification | |||
non-TNBC subtype | 370 | 71 (19.2%) | 0.000 |
TNBC subtype | 70 | 62 (88.6%) | Â |
